Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Other equities analysts also recently issued research reports about the stock. Chardan Capital reiterated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Trading Up 7.4 %

NASDAQ:MCRB traded up $0.06 during mid-day trading on Friday, hitting $0.91. The stock had a trading volume of 1,518,476 shares, compared to its average volume of 1,304,388. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.05. The stock has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.90. The company has a market capitalization of $154.59 million, a PE ratio of -3.94 and a beta of 2.07.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. FMR LLC boosted its stake in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares during the period. Geode Capital Management LLC raised its stake in Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after acquiring an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of Seres Therapeutics in the 3rd quarter valued at approximately $374,000. Finally, State Street Corp increased its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 43,700 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.